News

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Series C – $12 Million

Advanced Data Analytics, Long-Term and Logitudinal Studies for Healthspan

Hevolutions’ Global Healthspan Summit 2025

February 5, 2025

Dr. Nikole Kimes presents at the opening panel: The Present and Future of the Microbiome Industry

Microbiome Times Partnering Forum

Siolta successfully doses first newborn in phase 2 study

Groundbreaking trial of STMC-103H for the prevention of atopic diseases

Siolta Therapeutics awarded NIH grant funding

Advance Technology Small Business Innovation Grant Award from NIAID

February 9, 2022

Siolta Collaboration with Bio-Me

Microbiome-based Prognostics for Early Identification of Allergy and Asthma

November 23, 2020

Siolta Therapeutics closes financing round to support clinical development of lead program

Series B – $30 Million

September 22, 2020

FDA grants Fast Track status to Siolta Therapeutics lead clinical program

Fast Track Designation

Siolta Therapeutics expands its executive advisory team

Welcome to Dr. John Martin former CEO/Chairperson of Gilead

January 28, 2020

Older